Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval
June 7, 2016 7:50 AM EDTprice target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying the dystrophin request is the best-case scenario, but they still see a slim chance of approval.
Wang commented, "We see FDA's request for additional... More
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM EDTOppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More
Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
June 7, 2016 6:16 AM EDTLeerink affirms Sarepta (Nasdaq: SRPT) at Underperform with a price target of $5 after the company announced that the U.S. Food and Drug... More
Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDA
June 6, 2016 5:45 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is gaining sharply after the company announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing... More
